Privacy policy Terms + conditions

©2022 Gate Neurosciences. All rights reserved.

News & Publications

09/29/2022
Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update

Gate Neurosciences today announced the results of research, published in the International Journal of Neuropsychopharmacology, supporting the mechanism of action and clinical foundation of Zelquistinel – the company’s lead oral program in Phase 2 development – as a rapid-acting, long-lasting and safe antidepressant.

Press Release
08/23/2022
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases

Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.

Press Release
07/26/2022
Zelquistinel is an Orally Bioavailable Novel NMDAR Modulator that Exhibits Rapid & Sustained Antidepressant Effects

Highlights our lead program, Zelquistinel, and it’s unique mechanism of positive NMDA receptor modulation and that enhances long-term potentiation and synaptic function, resulting in rapid and sustained antidepressant activity with an improved safety profile versus NMDA antagonists.

Publication
06/17/2022
Repeated Administration of Rapastinel Produces Prolonged Rescue of Memory Deficits in Mice Treated with NMDAR Antagonists

Highlights the differentiated mechanism and effects on cognition of our class of NMDAR modulators, compared to NMDAR antagonists. Gate’s unique NMDAR modulator mechanism reverses and rescues brain deficits caused by NMDAR antagonists such as PCP and ketamine.

Publication
10/15/2020
Positive Modulation of NMDA Receptors by AGN-241751 exerts rapid antidepressant effects via Excitatory Neurons

Highlights our lead program, Zelquistinel, and the novel NMDAR mechanism by which our compounds act on excitatory neurons in the mPFC, but not inhibitory neurons, to drive antidepressant effects

Publication
09/21/2022
Cell-Type Specific Modulation of NMDA Receptors Triggers Antidepressant Actions

Highlights and differentiates the mechanistic pathways by which Gate’s NMDAR positive modulators, and NMDA antagonists (ie ketamine), can both exert rapid antidepressant effects. Gate’s NMDA modulators directly enhance receptor function on principal glutamatergic neurons in the mPFC, whereas antagonists block NMDA on GABA interneurons causing a glutamate efflux (and dissociative side effects) and indirect activation of excitatory synapse.

Publication
08/13/2020
Rapastinel Alleviates the Neurotoxic Effects Induced by NMDA Receptor Blockade

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

Publication
02/04/2020
NMDAR Modulators as Rapid Antidepressants, Converging and Distinct Signaling Mechanisms

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

Publication
08/05/2020
Rapastinel, an NMDAR positive modulator, produces distinct behavioral, sleep, and EEG profiles compared with ketamine

Highlights Gate’s NMDAR modulators lower propensity than ketamine to induce CNS-related adverse side effects and sleep disturbances.

Publication
11/13/2019
Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms

Highlights how Gate’s NMDAR modulators exert rapid (within hours) and long-lasting (7-10 days) of antidepressants but without has no ketamine-like side effect such as cognitive impairment and psychotomimetic symptoms.

Publication
1 2